Vitamin D Status and Clinical Outcomes in Acute Respiratory Distress Syndrome: A Secondary Analysis From the Assessment of Low Tidal Volume and Elevated End-Expiratory Volume to Obviate Lung Injury (ALVEOLI) Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Acute respiratory distress syndrome (ARDS) is a highly morbid condition that has limited therapeutic options.

Who Took Part

According to the abstract, 549 patients were involved.

The researchers performed a secondary analysis of data from a randomized, controlled trial comparing oxygenation strategies in 549 patients with ARDS (NCT00000579).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Baseline 25OHD was measured in stored plasma samples.

Analyses were adjusted for age, race, and Acute Physiology and Chronic Health Evaluation III score.

What Was Measured

Topics PubMed links to this paper include Lung Injury, Respiration, Artificial, Respiratory Distress Syndrome, Tidal Volume and Vitamin D.

The authors tagged it with the keywords ARDS, ICU, critical care and mechanical ventilation.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 549 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Journal of intensive care medicine), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.